| Mr Raymond F O'brien, LCSW | |
|
2580 N Rancho Dr, Suite 104a, North Las Vegas, NV 89032 | |
| (702) 825-0729 | |
| Not Available |
| Full Name | Mr Raymond F O'brien |
|---|---|
| Gender | Male |
| Speciality | Social Worker - Clinical |
| Location | 2580 N Rancho Dr, North Las Vegas, Nevada |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144472770 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 5824-C (Nevada) | Primary |
| Entity Name | Mind Power Behavioral Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851871768 PECOS PAC ID: 5890046916 Enrollment ID: O20180927003094 |
News Archive
ArQule, Inc. today announced that the following presentations of clinical data for ARQ 197, a selective inhibitor of the c-Met receptor tyrosine kinase, will take place at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 4-8, 2010 in Chicago, Illinois.
Adeona Pharmaceuticals, Inc. announced the completion of 50% enrollment in Part 2 of its clinical study, A Prospective, Randomized, Double Blind Trial of a Novel Oral Zinc Cysteine Preparation in Alzheimer's Disease (CopperProof-2).
Fitch Ratings sees an active year for new drug applications to be registered to U.S. and European drug regulators considering recent updates to the pharmaceutical industry's late-stage R&D programs. According to Fitch's new Global Pharmaceutical R&D Pipeline report, the Fitch-rated pharmaceutical developers listed in the report plan on submitting marketing applications to the U.S. Food & Drug Administration (FDA) or the European Medicines Agency (EMEA) during 2010 for approval of 22 novel drug therapies.
Women 40 years and younger with early-stage breast cancer who receive an additional high dose of radiation (boost dose) after undergoing breast-conserving surgery (lumpectomy) and standard radiation treatment are almost twice as likely to be free of cancer 10 years after treatment compared to those who don't receive the boost dose, according to a large European study presented at the Plenary I session on October 29, 2007, at the American Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in Los Angeles.
› Verified 2 days ago
| Entity Name | Brain Power Medical Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265109011 PECOS PAC ID: 4486051901 Enrollment ID: O20210927002296 |
News Archive
ArQule, Inc. today announced that the following presentations of clinical data for ARQ 197, a selective inhibitor of the c-Met receptor tyrosine kinase, will take place at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 4-8, 2010 in Chicago, Illinois.
Adeona Pharmaceuticals, Inc. announced the completion of 50% enrollment in Part 2 of its clinical study, A Prospective, Randomized, Double Blind Trial of a Novel Oral Zinc Cysteine Preparation in Alzheimer's Disease (CopperProof-2).
Fitch Ratings sees an active year for new drug applications to be registered to U.S. and European drug regulators considering recent updates to the pharmaceutical industry's late-stage R&D programs. According to Fitch's new Global Pharmaceutical R&D Pipeline report, the Fitch-rated pharmaceutical developers listed in the report plan on submitting marketing applications to the U.S. Food & Drug Administration (FDA) or the European Medicines Agency (EMEA) during 2010 for approval of 22 novel drug therapies.
Women 40 years and younger with early-stage breast cancer who receive an additional high dose of radiation (boost dose) after undergoing breast-conserving surgery (lumpectomy) and standard radiation treatment are almost twice as likely to be free of cancer 10 years after treatment compared to those who don't receive the boost dose, according to a large European study presented at the Plenary I session on October 29, 2007, at the American Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in Los Angeles.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Raymond F O'brien, LCSW 2580 N Rancho Dr, Suite 104a, North Las Vegas, NV 89032 Ph: (702) 825-0729 | Mr Raymond F O'brien, LCSW 2580 N Rancho Dr, Suite 104a, North Las Vegas, NV 89032 Ph: (702) 825-0729 |
News Archive
ArQule, Inc. today announced that the following presentations of clinical data for ARQ 197, a selective inhibitor of the c-Met receptor tyrosine kinase, will take place at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 4-8, 2010 in Chicago, Illinois.
Adeona Pharmaceuticals, Inc. announced the completion of 50% enrollment in Part 2 of its clinical study, A Prospective, Randomized, Double Blind Trial of a Novel Oral Zinc Cysteine Preparation in Alzheimer's Disease (CopperProof-2).
Fitch Ratings sees an active year for new drug applications to be registered to U.S. and European drug regulators considering recent updates to the pharmaceutical industry's late-stage R&D programs. According to Fitch's new Global Pharmaceutical R&D Pipeline report, the Fitch-rated pharmaceutical developers listed in the report plan on submitting marketing applications to the U.S. Food & Drug Administration (FDA) or the European Medicines Agency (EMEA) during 2010 for approval of 22 novel drug therapies.
Women 40 years and younger with early-stage breast cancer who receive an additional high dose of radiation (boost dose) after undergoing breast-conserving surgery (lumpectomy) and standard radiation treatment are almost twice as likely to be free of cancer 10 years after treatment compared to those who don't receive the boost dose, according to a large European study presented at the Plenary I session on October 29, 2007, at the American Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in Los Angeles.
› Verified 2 days ago
Courtney B Jordan, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 6900 N Pecos Rd, North Las Vegas, NV 89086 Phone: 027-791-9000 | |
Erica Losoya-wood, LCSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 6900 N Pecos Rd, North Las Vegas, NV 89086 Phone: 702-791-9000 | |
Shakira D Nelson, LCSW, LCAS Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 6900 N Pecos Rd, North Las Vegas, NV 89086 Phone: 702-791-9000 | |
Ms. Brittany N. Robinson, MSW, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 6900 N Pecos Rd, North Las Vegas, NV 89086 Phone: 702-791-9000 | |
Lucas Nathan Dalton, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 6900 N Pecos Rd, North Las Vegas, NV 89086 Phone: 702-350-0760 | |
Justin Lamb, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 6900 N Pecos Rd, North Las Vegas, NV 89086 Phone: 702-791-9000 | |
Miss Brittney M Mccadney, LCSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 3333 Landing Bird Ct, North Las Vegas, NV 89032 Phone: 708-522-7181 |